 |  |  |
| | |
| | |
|
| |||||||||
|
| PR Newswire · Aktuelle PR Newswire Nachrichten · Archiv< zurück < · Druckversion |
| 31.10.2006 14:07 |
Osteologix to Present at the 8th Annual Rodman and Renshaw Healthcare Conference |
|
SAN FRANCISCO, Oct. 31 /PRNewswire-FirstCall/ -- Osteologix, Inc. (BULLETIN BOARD: OLGX) announced today that Charles J. Casamento, CEO and President of Osteologix, will present an overview of the company and its new product under development for the treatment of osteoporosis at the 8th Annual Rodman and Renshaw Healthcare Conference in New York on Monday, November 6th at 3:55 p.m. local time. The presentation will be webcast live and will be available at http://www.wsw.com/webcast/rrshq10/olgx.ob/ . It will also be archived for a limited time after the presentation and will be available on the company's website at http://www.osteologix.com/ . About Osteologix Osteologix develops innovative products for the treatment of important unmet medical needs in bone disease and women's health. The company's lead product, NB S101, is entering Phase II clinical trials for the treatment of osteoporosis. It is believed that NB S101 may both increase new bone formation and decrease bone resorption. No other product currently on the US market simultaneously increases bone formation and decreases bone resorption. On May 24, 2006 Osteologix merged with a public shell company while completing a side by side financing managed by Rodman&Renshaw and Roth Capital Partners. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Osteologix can be obtained on the Company's website, http://www.osteologix.com/ . FORWARD-LOOKING STATEMENTS: Certain of the statements set forth in this press release constitute "Forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward looking statements involve risks and uncertainties, including, but not limited to: statements regarding Osteologix's research and development programs; proposed marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; and the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with pharmaceutical companies. There can be no assurance that such forward-looking statements will prove to be accurate and Osteologix undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. © 2010 PR Newswire Klicken Sie hier, um weitere aktuelle Nachrichten zum Unternehmen zu finden: OSTEOLOGIX News |
| Diesen Artikel bookmarken bei ...
|
| Wie bewerten Sie die aktuell angezeigte Seite? sehr gut 1 2 3 4 5 6 schlecht |
|
Startseite ·
Nachrichten ·
Aktienkurse ·
Xetra-Orderbuch ·
Nachrichten-Watchlist Ad hoc-Mitteilungen · Medien · Impressum | AGB | Disclaimer · Presse · Mediadaten |
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage  |
| © 2000-2010 FinanzNachrichten.de: Aktie, Aktien, Aktienkurse, Nachrichten FinanzNachrichten.de übernimmt keine Haftung für die Richtigkeit der Angaben! Kurse: Lang & Schwarz Wertpapierhandel AG · News-Kooperation: Investor Verlag |